1. Proposed sale of Y-mAbs to SERB Pharmaceuticals announced. 2. Shareholders to receive $8.60 per share in cash. 3. Kahn Swick & Foti investigating the sale's adequacy. 4. Consideration may undervalue Y-mAbs, raising legal concerns. 5. Transaction structured as a tender offer, emphasizing urgency.
While the sale offers a cash payout, concerns about undervaluation may deter buyers. Past tender offers have been contentious, impacting shareholder sentiment.
The potential undervaluation identified by KSF and investor reaction are critical. As this sale impacts shareholder value directly, it's relevant to YMAB's market position.
Immediate attention due to the tender offer may lead to short-term volatility. Historical examples show quick reactions in similar acquisition scenarios.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) to SERB Pharmaceuticals. Under the terms of the proposed transaction, shareholders of Y-mAbs will receive $8.60 in cash for each share of Y-mAbs that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-ymab/ to learn more.
Please note that the transaction is structured as a tender offer, such that time may be of the essence.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
1100 Poydras St., Suite 960
New Orleans, LA 70163
CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20250807034703/en/
Lewis S. Kahn
lewis.kahn@ksfcounsel.com
855-768-1857